Clinical and molecular features of patients with amyotrophic lateral sclerosis and SOD1 mutations: a monocentric study

Frontiers in Neurology

Neurology

Antonia Ratti¹  Paolo Ripellino²  Claudio Gobbi³  Sara Antognozzi⁴  Dario Ronchi⁴  Roberto Del Bo⁴  Nicola Ticozzi⁵  Vincenzo Silani⁵  Megi Meneri⁶  Delia Gagliardi⁶  Stefania Corti⁶  Giacomo Pietro Comi⁷ 

[1] Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy;Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milan, Italy;Department of Neurology, Neurocenter of Southern Switzerland EOC, Lugano, Switzerland;Department of Neurology, Neurocenter of Southern Switzerland EOC, Lugano, Switzerland;Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland;Neuroscience Section, Department of Pathophysiology and Transplantation (DEPT), Dino Ferrari Centre, University of Milan, Milan, Italy;Neuroscience Section, Department of Pathophysiology and Transplantation (DEPT), Dino Ferrari Centre, University of Milan, Milan, Italy;Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy;Neuroscience Section, Department of Pathophysiology and Transplantation (DEPT), Dino Ferrari Centre, University of Milan, Milan, Italy;Neurology Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy;Neuroscience Section, Department of Pathophysiology and Transplantation (DEPT), Dino Ferrari Centre, University of Milan, Milan, Italy;Neuromuscular and Rare Diseases Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy;

关键词: amyotrophic lateral sclerosis;    superoxide dismutase;    SOD1;    cohort;    SOD1;   

DOI  :  10.3389/fneur.2023.1169689

 received in 2023-02-19, accepted in 2023-04-19,  发布年份 2023

来源: Frontiers

【 摘 要 】

IntroductionSOD1 was the first gene associated with both familial and sporadic forms of amyotrophic lateral sclerosis (ALS) and is the second most mutated gene in Caucasian ALS patients. Given their high clinical and molecular heterogeneity, a detailed characterization of SOD1-ALS patients could improve knowledge about the natural history of this disease. Here, the authors aimed to provide a clinical and molecular description of a monocentric cohort of SOD1-ALS patients.MethodsAmyotrophic lateral sclerosis (ALS) patients referring to the neurology unit of our center between 2008 and 2021 were clinically assessed and underwent molecular testing for SOD1. Segregation studies in available family members and in silico analysis were performed to sustain the pathogenicity of the identified SOD1 variants.ResultsAmong the 576 patients in our cohort, we identified 19 individuals harboring a mutation in SOD1 (3.3%), including 15 (78.9%) with a familial and four (21.1%) with a sporadic form. The spinal onset of the disease was observed in all patients, and survival was extremely variable, ranging from 8 months to over 30 years. Twelve different SOD1 missense variants were identified in our cohort, including one novel mutation (p.Pro67Leu).DiscussionIn the present series, we provided the first description of an Italian monocentric cohort of SOD1-ALS patients, and we expanded the repertoire of SOD1 mutations. Our cohort presents several remarkable features, including variable expressivity in the same family, atypical presentation (ataxia, cognitive impairment, and other extra-motor symptoms), and different modes of inheritance of a given mutation in the same family. Given the recent authorization of SOD1-directed antisense oligonucleotide for use in SOD1-ALS patients, we recommend prompt screening for SOD1 mutations in novel ALS patients with familiar or sporadic presentations.

【 授权许可】

Unknown   
Copyright © 2023 Gagliardi, Ripellino, Meneri, Del Bo, Antognozzi, Comi, Gobbi, Ratti, Ticozzi, Silani, Ronchi and Corti.